NO324498B1 - Mikro-smadrape og steril injiserbar farmasoytisk blanding - Google Patents
Mikro-smadrape og steril injiserbar farmasoytisk blanding Download PDFInfo
- Publication number
- NO324498B1 NO324498B1 NO19984370A NO984370A NO324498B1 NO 324498 B1 NO324498 B1 NO 324498B1 NO 19984370 A NO19984370 A NO 19984370A NO 984370 A NO984370 A NO 984370A NO 324498 B1 NO324498 B1 NO 324498B1
- Authority
- NO
- Norway
- Prior art keywords
- propofol
- micro
- droplet
- volume
- droplets
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims abstract description 113
- 229960004134 propofol Drugs 0.000 claims abstract description 101
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 10
- 230000001580 bacterial effect Effects 0.000 claims abstract description 9
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 7
- 239000003921 oil Substances 0.000 claims abstract description 4
- 238000004581 coalescence Methods 0.000 claims abstract 2
- 238000000265 homogenisation Methods 0.000 claims abstract 2
- 238000000527 sonication Methods 0.000 claims description 6
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 239000000644 isotonic solution Substances 0.000 claims 1
- 125000005457 triglyceride group Chemical group 0.000 claims 1
- 239000003925 fat Substances 0.000 abstract description 10
- 230000000845 anti-microbial effect Effects 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 239000012528 membrane Substances 0.000 abstract description 2
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 230000003019 stabilising effect Effects 0.000 abstract 1
- 229940072271 diprivan Drugs 0.000 description 15
- 238000000149 argon plasma sintering Methods 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 239000004045 soybean oil emulsion Substances 0.000 description 13
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 11
- 239000000787 lecithin Substances 0.000 description 11
- 229940067606 lecithin Drugs 0.000 description 11
- 235000010445 lecithin Nutrition 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 206010002091 Anaesthesia Diseases 0.000 description 8
- 230000037005 anaesthesia Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000024188 startle response Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 206010039897 Sedation Diseases 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000036280 sedation Effects 0.000 description 5
- 235000012424 soybean oil Nutrition 0.000 description 5
- 239000003549 soybean oil Substances 0.000 description 5
- 208000003443 Unconsciousness Diseases 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- -1 10 mg/ml Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 230000028527 righting reflex Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical class OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- KILNVBDSWZSGLL-UHFFFAOYSA-O 2-[2,3-di(hexadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-UHFFFAOYSA-O 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010074028 Fat overload syndrome Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000010441 alabaster Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 239000002869 intravenous anesthetic agent Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Motorcycle And Bicycle Frame (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/616,511 US5637625A (en) | 1996-03-19 | 1996-03-19 | Propofol microdroplet formulations |
PCT/US1997/004168 WO1997034588A1 (en) | 1996-03-19 | 1997-03-17 | Propofol microdroplet formulations |
Publications (3)
Publication Number | Publication Date |
---|---|
NO984370L NO984370L (no) | 1998-09-18 |
NO984370D0 NO984370D0 (no) | 1998-09-18 |
NO324498B1 true NO324498B1 (no) | 2007-10-29 |
Family
ID=24469788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19984370A NO324498B1 (no) | 1996-03-19 | 1998-09-18 | Mikro-smadrape og steril injiserbar farmasoytisk blanding |
Country Status (19)
Country | Link |
---|---|
US (1) | US5637625A (ja) |
EP (1) | EP0796616B1 (ja) |
JP (1) | JP2000507244A (ja) |
KR (1) | KR100484516B1 (ja) |
CN (1) | CN1124845C (ja) |
AT (1) | ATE182074T1 (ja) |
AU (1) | AU719756B2 (ja) |
BR (1) | BR9708099B8 (ja) |
CA (1) | CA2249375C (ja) |
DE (1) | DE69700317T2 (ja) |
DK (1) | DK0796616T3 (ja) |
ES (1) | ES2135969T3 (ja) |
FI (1) | FI982009A0 (ja) |
GR (1) | GR3031414T3 (ja) |
HU (1) | HU225046B1 (ja) |
NO (1) | NO324498B1 (ja) |
NZ (1) | NZ331669A (ja) |
RU (1) | RU2186564C2 (ja) |
WO (1) | WO1997034588A1 (ja) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070117862A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
AU709262B2 (en) * | 1995-10-17 | 1999-08-26 | Board Of Regents, The University Of Texas System | Insoluble drug delivery |
US7255877B2 (en) * | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
US6465016B2 (en) * | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
CH692322A5 (it) * | 1997-05-26 | 2002-05-15 | Westy Ag | Formulazione iniettabile limpida di Propofol. |
IL133672A0 (en) * | 1997-06-27 | 2001-04-30 | Vivorx Pharmaceuticals Inc | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6638621B2 (en) * | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
BR9907832A (pt) * | 1998-02-10 | 2000-10-31 | Sicor Inc | Composição de propofol contendo sulfito |
WO1999040906A2 (en) * | 1998-02-11 | 1999-08-19 | Research Triangle Pharmaceuticals | Method and composition for treatment of inflammatory conditions |
US6254853B1 (en) * | 1998-05-08 | 2001-07-03 | Vyrex Corporation | Water soluble pro-drugs of propofol |
ATE259220T1 (de) | 1998-05-29 | 2004-02-15 | Skyepharma Canada Inc | Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben |
US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
US7097849B2 (en) * | 1998-08-19 | 2006-08-29 | Jagotec Ag | Injectable aqueous dispersions of propofol |
US6150423A (en) | 1998-10-15 | 2000-11-21 | Phoenix Scientific, Inc. | Propofol-based anesthetic and method of making same |
US6140374A (en) * | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
RU2233654C2 (ru) | 1998-11-20 | 2004-08-10 | Ртп Фарма Инк. | Диспергируемые стабилизированные фосфолипидом микрочастицы |
EP1143962B1 (en) * | 1999-01-28 | 2004-11-24 | Dinesh Shantilal Patel | Parenteral solution of propofol (2,6-diisoprophylphenol) and 2.5-di-0-methyl-1.4;3.6-dianhydro-d-glucitol as a solvent |
US6177477B1 (en) * | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
US6100302A (en) * | 1999-04-05 | 2000-08-08 | Baxter International Inc. | Propofol formulation with enhanced microbial characteristics |
GB2350297A (en) * | 1999-05-27 | 2000-11-29 | Abbott Lab | Injectable halogenated anesthetic formulation in emulsion form |
IL148685A0 (en) * | 1999-09-21 | 2002-09-12 | Rtp Pharma Inc | Surface modified particulate compositions of biologically active substances |
US6071933A (en) * | 1999-12-03 | 2000-06-06 | Diversified Medical Innovations, Inc. | Homogeneous remifentanil-propofol blend for patient controlled anesthesia and process for its use |
GB2359747B (en) * | 2000-02-29 | 2002-04-24 | Maelor Pharmaceuticals Ltd | Anaesthetic formulations |
ES2469642T3 (es) | 2000-04-20 | 2014-06-18 | Jagotec Ag | Procedimiento mejorado para partículas de fármaco insoluble en agua |
JP2003535884A (ja) | 2000-06-16 | 2003-12-02 | スカイファーマ・カナダ・インコーポレーテッド | プロポフォールの改善された注射可能な分散物 |
US6623765B1 (en) | 2000-08-01 | 2003-09-23 | University Of Florida, Research Foundation, Incorporated | Microemulsion and micelle systems for solubilizing drugs |
US6634576B2 (en) | 2000-08-31 | 2003-10-21 | Rtp Pharma Inc. | Milled particles |
ES2372746T3 (es) * | 2000-09-20 | 2012-01-26 | Jagotec Ag | Micropartículas de fibrato estabilizadas. |
US8586094B2 (en) | 2000-09-20 | 2013-11-19 | Jagotec Ag | Coated tablets |
WO2002067901A1 (en) * | 2001-02-22 | 2002-09-06 | Skyepharma Canada Inc. | Fibrate-statin combinations with reduced fed-fasted effects |
US6991809B2 (en) | 2001-06-23 | 2006-01-31 | Lyotropic Therapeutics, Inc. | Particles with improved solubilization capacity |
US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
WO2003026632A2 (en) | 2001-09-26 | 2003-04-03 | Theravance, Inc. | Substituted phenol compounds useful for anesthesia and sedation |
AU2002337692B2 (en) * | 2001-09-26 | 2007-09-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
KR20040080444A (ko) * | 2001-12-28 | 2004-09-18 | 길포드 파마슈티컬스 인코포레이티드 | 수용성인 프로포폴 전구약물의 약학적 수성 제제 |
US20080220075A1 (en) * | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
AU2003230691A1 (en) * | 2002-03-20 | 2003-10-08 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
NZ535484A (en) * | 2002-04-08 | 2009-01-31 | Mgi Gp Inc | Pharmaceutical compositions containing fospropofol (O-phosphonooxymethylpropofol) and methods of administering same |
WO2004010941A2 (en) * | 2002-07-29 | 2004-02-05 | Transform Pharmaceuticals, Inc. | Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
US20040220283A1 (en) * | 2002-07-29 | 2004-11-04 | Transform Pharmaceuticals, Inc. | Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
US7550155B2 (en) * | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
AU2003286725B2 (en) * | 2002-10-29 | 2007-07-12 | Transform Pharmaceuticals, Inc. | Propofol with cysteine |
CA2508441A1 (en) * | 2002-12-06 | 2004-06-24 | Otsuka Pharmaceutical Factory, Inc. | Propofol-containing fat emulsions |
US20040225022A1 (en) * | 2003-05-09 | 2004-11-11 | Desai Neil P. | Propofol formulation containing reduced oil and surfactants |
US8476010B2 (en) | 2003-07-10 | 2013-07-02 | App Pharmaceuticals Llc | Propofol formulations with non-reactive container closures |
US7182948B2 (en) * | 2003-08-04 | 2007-02-27 | Ko Manufacturing, Inc. | Topical veterinary compositions and methods for the treatment and prevention of infection |
US20050238705A1 (en) * | 2004-01-14 | 2005-10-27 | Ning Hu | Lipid-based dispersions useful for drug delivery |
US7125954B2 (en) | 2005-01-27 | 2006-10-24 | General Electric Company | Method for producing polyether polymers |
WO2006138202A2 (en) * | 2005-06-14 | 2006-12-28 | Baxter International Inc. | Pharmaceutical formulations for minimizing drug-drug interactions |
CA2620585C (en) * | 2005-08-31 | 2015-04-28 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
KR101643416B1 (ko) * | 2005-08-31 | 2016-07-27 | 아브락시스 바이오사이언스, 엘엘씨 | 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법 |
US20070134341A1 (en) * | 2005-11-15 | 2007-06-14 | Kipp James E | Compositions of lipoxygenase inhibitors |
US8722736B2 (en) * | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
RU2535001C1 (ru) * | 2013-07-11 | 2014-12-10 | Общество с ограниченной ответственностью "ВИК-здоровье животных" | Микроколлоидный раствор пропофола для анестезии |
US20160346219A1 (en) | 2015-06-01 | 2016-12-01 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
TW201705941A (zh) * | 2015-06-01 | 2017-02-16 | 奧托德里克有限公司 | 經磷脂塗覆的治療劑奈米粒子及其相關方法 |
WO2017218630A2 (en) * | 2016-06-15 | 2017-12-21 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
BR112022005497A2 (pt) * | 2019-12-20 | 2022-06-21 | Fresenius Kabi Austria Gmbh | Método para produzir emulsões de óleo em água |
EP4056038A1 (en) * | 2021-03-10 | 2022-09-14 | Basf Se | Microparticles containing active substances |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4798846A (en) * | 1974-03-28 | 1989-01-17 | Imperial Chemical Industries Plc | Pharmaceutical compositions |
GB1472793A (en) * | 1974-03-28 | 1977-05-04 | Ici Ltd | Pharmaceutical compositions |
US4725442A (en) * | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
US4622219A (en) * | 1983-06-17 | 1986-11-11 | Haynes Duncan H | Method of inducing local anesthesia using microdroplets of a general anesthetic |
DE4132677C2 (de) * | 1991-10-01 | 1995-08-24 | Braun Melsungen Ag | Flüchtige Inhalationsnarkotika enthaltende Liposomen, ihre Herstellung und Verwendung |
GB9405593D0 (en) * | 1994-03-22 | 1994-05-11 | Zeneca Ltd | Pharmaceutical compositions |
US5496537A (en) * | 1995-03-23 | 1996-03-05 | Henry; Richard A. | Propofol hydrofluorocarbon propellant formulations |
-
1996
- 1996-03-19 US US08/616,511 patent/US5637625A/en not_active Expired - Lifetime
-
1997
- 1997-03-17 NZ NZ331669A patent/NZ331669A/xx not_active IP Right Cessation
- 1997-03-17 HU HU9902553A patent/HU225046B1/hu not_active IP Right Cessation
- 1997-03-17 BR BRPI9708099-3B8A patent/BR9708099B8/pt active IP Right Grant
- 1997-03-17 AU AU23292/97A patent/AU719756B2/en not_active Ceased
- 1997-03-17 KR KR10-1998-0707525A patent/KR100484516B1/ko not_active IP Right Cessation
- 1997-03-17 RU RU98118914/14A patent/RU2186564C2/ru not_active IP Right Cessation
- 1997-03-17 WO PCT/US1997/004168 patent/WO1997034588A1/en not_active Application Discontinuation
- 1997-03-17 CN CN97194485A patent/CN1124845C/zh not_active Expired - Fee Related
- 1997-03-17 CA CA002249375A patent/CA2249375C/en not_active Expired - Fee Related
- 1997-03-17 JP JP9533579A patent/JP2000507244A/ja active Pending
- 1997-03-19 DK DK97301839T patent/DK0796616T3/da active
- 1997-03-19 DE DE69700317T patent/DE69700317T2/de not_active Expired - Lifetime
- 1997-03-19 ES ES97301839T patent/ES2135969T3/es not_active Expired - Lifetime
- 1997-03-19 EP EP97301839A patent/EP0796616B1/en not_active Expired - Lifetime
- 1997-03-19 AT AT97301839T patent/ATE182074T1/de active
-
1998
- 1998-09-17 FI FI982009A patent/FI982009A0/fi not_active IP Right Cessation
- 1998-09-18 NO NO19984370A patent/NO324498B1/no not_active IP Right Cessation
-
1999
- 1999-10-07 GR GR990402503T patent/GR3031414T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
RU2186564C2 (ru) | 2002-08-10 |
AU719756B2 (en) | 2000-05-18 |
AU2329297A (en) | 1997-10-10 |
CN1124845C (zh) | 2003-10-22 |
JP2000507244A (ja) | 2000-06-13 |
KR20000064762A (ko) | 2000-11-06 |
CA2249375C (en) | 2002-06-18 |
BR9708099B8 (pt) | 2014-04-29 |
NO984370L (no) | 1998-09-18 |
WO1997034588A1 (en) | 1997-09-25 |
HUP9902553A2 (hu) | 2000-10-28 |
HU225046B1 (hu) | 2006-05-29 |
DE69700317D1 (de) | 1999-08-19 |
NZ331669A (en) | 2000-01-28 |
NO984370D0 (no) | 1998-09-18 |
KR100484516B1 (ko) | 2005-09-02 |
CN1218398A (zh) | 1999-06-02 |
ATE182074T1 (de) | 1999-07-15 |
GR3031414T3 (en) | 2000-01-31 |
FI982009A (fi) | 1998-09-17 |
DE69700317T2 (de) | 1999-12-02 |
CA2249375A1 (en) | 1997-09-25 |
DK0796616T3 (da) | 1999-11-29 |
FI982009A0 (fi) | 1998-09-17 |
BR9708099A (pt) | 2000-01-04 |
ES2135969T3 (es) | 1999-11-01 |
HUP9902553A3 (en) | 2001-04-28 |
US5637625A (en) | 1997-06-10 |
BR9708099B1 (pt) | 2010-02-23 |
EP0796616A1 (en) | 1997-09-24 |
EP0796616B1 (en) | 1999-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO324498B1 (no) | Mikro-smadrape og steril injiserbar farmasoytisk blanding | |
Hippalgaonkar et al. | Injectable lipid emulsions—advancements, opportunities and challenges | |
US5091187A (en) | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs | |
US5091188A (en) | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs | |
Driscoll et al. | Physicochemical stability assessments of lipid emulsions of varying oil composition | |
US4687661A (en) | Method for producing liposomes | |
JP2589173B2 (ja) | 少層脂質小胞 | |
CN101019833B (zh) | 一种用作药物载体的药用油包油型非水微乳及其药物制剂 | |
US9333180B2 (en) | Nanocapsules with a liquid lipid core charged with water-soluble or water-dispersible active agents | |
Lixin et al. | A less irritant norcantharidin lipid microspheres: formulation and drug distribution | |
Tamilvanan | Formulation of multifunctional oil-in-water nanosized emulsions for active and passive targeting of drugs to otherwise inaccessible internal organs of the human body | |
US20240261254A1 (en) | Dihydromyricetin nanoemulsion formulations and methods for forming them | |
Tenambergen et al. | Dual asymmetric centrifugation as an alternative preparation method for parenteral fat emulsions in preformulation development | |
Zhang et al. | Submicron lipid emulsions: a versatile platform for drug delivery | |
Yalin et al. | Preparation and properties of a stable intravenous lorazepam emulsion | |
Esquisabel et al. | Effect of lecithins on BCG-alginate-PLL microcapsule particle size and stability upon storage | |
JPH02167217A (ja) | 乳化組成物 | |
Weng et al. | Formulation, preparation, and stability of intravenous bufadienolides‐loaded lipid microspheres | |
Frézard et al. | Liposome-encapsulated neuropeptides for site-specific microinjection | |
KR20030039331A (ko) | 구조화된 암포테리신 b 유제 | |
CN107184550B (zh) | 一种前列地尔注射液的制备方法 | |
Wu | Parenteral nanoemulsions: composition, preparation and cellular uptake | |
Gurung | Specific targeting with functionalized nanoemulsions | |
Abubakar et al. | NANOPARTICLES: A DELIVERY SYSTE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |